Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts. 

Further Listening:

Trillion Dollar Shot 

Why WeightWatchers Wants in on Drugs Like Ozempic  

Sign up for WSJ’s free What’s News newsletter.

Learn more about your ad choices. Visit megaphone.fm/adchoices